Chief Executive Officer & President · GALECTIN THERAPEUTICS INC (GALT)

Harold Shlevin

A named executive officer of GALECTIN THERAPEUTICS in every fiscal year CompBrief holds from FY2016 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$919,336

Salary $375,583Stock awards $0Bonus $335,000

FY2019: $1,306,507

2nd of 4 named executive officers at Galectin Therapeutics by FY2020 total.

4 named officers on file for GALECTIN THERAPEUTICS, FY2020

Harold Shlevin’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GALECTIN THERAPEUTICS’s whole pay program stands against its peers

  • GALECTIN THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GALT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed October 12, 2021 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Harold Shlevin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Harold Shlevin compensation by year

GALECTIN THERAPEUTICS Summary Compensation Table · all 5 fiscal years held
In US dollars, as GALECTIN THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020
Salary$260,000$260,000$395,833$500,000$375,583
Bonus$50,920$131,163$375,000$465,625$335,000
Stock awards$0$0$0$0$0
Option awards$140,587$0$891,113$268,196$154,266
Non-equity incentive$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0
All other$48,118$53,992$68,869$72,686$54,487
Total$499,625$445,155$1,730,815$1,306,507$919,336

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GALECTIN THERAPEUTICS INC DEF 14A filed October 12, 2021, accession 0001140361-21-034290, and prior-year filings.

How this page was built: the GALECTIN THERAPEUTICS INC filed document, accession 0001140361-21-034290. Every figure is read from that document and cited to the page and table it appears in. Filed October 12, 2021.

$500K
$445K
$1.7M
$1.3M
$919K
FY16
FY17
FY18
FY19
FY20
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option35,000—$4.72

Per the Outstanding Equity Awards at Fiscal Year-End table in GALECTIN THERAPEUTICS INC's FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

42 Form 4 lines since the FY2020 proxy (filed October 12, 2021)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-29Exercise or conversion derivative10b5-122,268$0.0030,000
2026-06-29Exercise or conversion10b5-122,268$1.2328,768
2026-06-29Sale10b5-122,268$5.046,500
2026-06-26Sale10b5-17,732$5.006,500
2026-06-26Exercise or conversion10b5-17,732$1.2314,232
2026-06-26Exercise or conversion derivative10b5-17,732$0.0052,268
2026-01-16Grant or award derivative—60,000$0.0060,000
2025-12-17Exercise or conversion10b5-120,000$1.9831,206

The 8 most recent of 42 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

GALECTIN THERAPEUTICS’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Pol BoudesChief Medical Officer$1,082,481
Harold Shlevin · this pageChief Executive Officer & President$919,336
Joel LewisChief Executive Officer & President$753,558
Jack CallicuttChief Financial Officer$720,372

Board service

GALECTIN THERAPEUTICS board · FY2021–FY2025
Director compensation in US dollars, as GALECTIN THERAPEUTICS reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$40,000$0$52,260$0$92,260
FY2024$40,000$0$58,000$0$98,000
FY2023$40,000$0$31,735$0$71,735
FY2022$35,000$0$58,934$0$114,200
FY2021$35,000$0$171,800$0$206,800

Each year as the company reported it in GALECTIN THERAPEUTICS's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: GALECTIN THERAPEUTICS pays directors a $35,000 cash retainer. As stated in GALECTIN THERAPEUTICS's FY2025 proxy.

The full GALECTIN THERAPEUTICS compensation record

free company brief

This page is one person within GALECTIN THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GALECTIN THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Harold Shlevin's compensation dossier · One-time report. No refunds.